May 15, 2017 10:12 AM EDT
Pharma

Can Den­dreon’s new Provenge da­ta help ig­nite a turn­around for the fad­ed can­cer star?

John Carroll

Editor & Founder

Two years ago, when Valeant bought Den­dreon and its prostate can­cer cell ther­a­py Provenge out of bank­rupt­cy for $400 mil­lion, ob­servers marked it as an­oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times